GLP-2 TZ
Price range: $60.00 through $80.00
- These products are intended for laboratory research purposes only, and are not for human or animal consumption. The products are not intended to diagnose, treat, cure, or prevent any disease. The products should not be used as a food, drug, cosmetic, or other household use.
Description
GLP-2 TZ is a 39-amino acid dual GIP and GLP-1 receptor agonist — classified as a twincretin — with a ~5-day half-life supporting once-weekly dosing. Clinical trials demonstrate superior glycemic control and weight reduction (15–22% mean body weight) compared to selective GLP-1 agonists, through simultaneous activation of two complementary incretin pathways.
Research Overview
GLP-2 TZ is engineered as a single peptide molecule activating both GIP and GLP-1 receptors with balanced affinity. GLP-1 receptor engagement promotes satiety signaling through central hypothalamic pathways, delays gastric emptying, and drives glucose-dependent insulin secretion while suppressing glucagon. GIP receptor engagement further amplifies insulin response to nutrients and is studied for its role in adipose tissue remodeling — differentiating it from pure GLP-1 agonists.
Clinical data from the SURPASS and SURMOUNT programs show consistent superiority over selective GLP-1 agonists for both HbA1c reduction and body weight outcomes, with a favorable profile attributed to the glucose-dependent nature of its insulin-stimulating activity.
Key Features
- 39-amino acid synthetic dual incretin peptide
- Simultaneous GIP and GLP-1 receptor agonism (twincretin classification)
- GLP-1 pathway: appetite suppression, gastric emptying delay, glucagon suppression
- GIP pathway: insulin sensitivity, postprandial insulin potentiation, fat tissue modulation
- Half-life: ~5 days; peak plasma concentration at ~1 day; once-weekly administration
- Clinical trials: 15–22% mean body weight reduction; superior glycemic control vs. GLP-1 mono-agonists
Common Research Uses
- Commonly studied for metabolic effects on body weight and body composition
- Researched in relation to type 2 diabetes glycemic management and HbA1c reduction
- Investigated for dual GIP/GLP-1 receptor co-activation and synergistic metabolic effects
- Studied in models of insulin resistance and cardiovascular metabolic risk
- Researched for appetite regulation and satiety hormone signaling
Product Specifications
- Format: Lyophilized powder
- Vial size: 30mg
- Storage: Freeze at −20°C (lyophilized); refrigerate at 2–8°C after reconstitution; use within 28 days
Disclaimer: For research purposes only. Not for human consumption.
